Erythromycin is a macrolide antibiotic that was first discovered in the 1940s and introduced into clinical practice in the 1950s. It is primarily used to treat bacterial infections caused by Gram-positive organisms and some Gram-negative bacteria, including respiratory tract infections, skin infections, and sexually transmitted infections. Erythromycin works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, which prevents translocation of peptides during translation. Its development offered an alternative to penicillin, particularly for patients with penicillinallergies, and it remains a key agent in the treatment of various infections, although its use has declined in favor of newer macrolides with improvedpharmacokinetic profiles and reduced gastrointestinal side effects.
BRAND NAMES
Erythrocin – widely used in tablet, capsule, and injectable forms.
E-Mycin – available for oral and parenteral administration.
Erythro – used in some regions for oral formulations.
MECHANISM OF ACTION
It binds reversibly to the 50S subunit of bacterial ribosomes, specifically near the peptidyl transferase center, which blocks the translocation of peptides during translation.
PHARMACOKINETICS
Absorption
Erythromycin is rapidly absorbed from the gastrointestinal tract after oral administration, but its bioavailability is variable (about 30–65%) due to acid degradation in the stomach.
Distribution
Erythromycin is widely distributed throughout body tissues and fluids, particularly in the liver, lungs, bile, and spleen, but it achieves lower concentrations in cerebrospinal fluid (CSF). It is approximately 70–90% protein-bound in plasma, mainly to albumin.
Metabolism
Erythromycin is extensively metabolized in the liver by the cytochrome P450 enzyme system, primarily CYP3A4. Its metabolism produces several inactive metabolites, which are eventually excreted in the bile.
Elimination
Erythromycin is primarily eliminated via hepatic metabolism, with most of the drug and its metabolites excreted in the bile into the feces. A small proportion (approximately 5–15%) is excreted unchanged in the urine.
PHARMACODYNAMICS
Erythromycin exerts its therapeutic effects by inhibiting bacterial protein synthesis. It binds to the 50S subunit of bacterial ribosomes, blocking the translocation of peptide chains during translation, which prevents bacterial growth and replication.
ADMINISTRATION
Erythromycin can be administered via oral, intravenous, or topical routes depending on the site and severity of the infection. Oral formulations, including tablets, capsules, and suspensions, are commonly used, with some preparations taken on an empty stomach to improve absorption, while others may be taken with food to reduce gastrointestinal irritation.
DOSAGE AND STRENGTH
Erythromycin is available in a variety of dosage forms and strengths to treat different types of infections. Oral tablets and capsules are commonly available in 250 mg, 333 mg, and 500 mg strengths, while oral suspensions are typically 125 mg/5 mL or 200 mg/5 mL.
DRUG INTERACTIONS
Erythromycin can interact with a variety of medications, primarily due to its inhibition of the CYP3A4 enzyme, which affects the metabolism of many drugs. Co-administration with statins such as simvastatin or atorvastatin may increase the risk of myopathy or rhabdomyolysis, while concurrent use with warfarin can enhance anticoagulant effects, raising the likelihood of bleeding.
FOOD INTERACTIONS
Erythromycin absorption can be affected by food, depending on the formulation. Standard erythromycin base tablets or capsules are best taken on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption, as food can reduce bioavailability.
CONTRAINDICATIONS
Erythromycin is contraindicated in patients with a known hypersensitivity to erythromycin, other macrolide antibiotics, or any component of the formulation, as this can trigger allergic reactions ranging from rash to anaphylaxis.
SIDE EFFECTS
Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea, dyspepsia
Hepatic: Cholestatic hepatitis, elevated liver enzymes, jaundice (rare)
Allergic reactions: Rash, urticaria, pruritus, rarely anaphylaxis
Cardiovascular: QT prolongation, arrhythmias, palpitations (especially in patients with underlying heart conditions)
Central nervous system: Headache, dizziness, vertigo
Other: Rare hearing disturbances (reversible), transient eosinophilia.
TOXICITY
Erythromycin toxicity is uncommon but can occur with overdose, prolonged therapy, or in patients with hepatic or cardiac impairment. Gastrointestinal symptoms such as severe nausea, vomiting, abdominal pain, and diarrhea are the most frequently observed signs of toxicity. Hepatic toxicity can manifest as cholestatic hepatitis, jaundice, and elevated liver enzymes, particularly in patients with pre-existing liver disease.
